Study #2015-0555
A Phase 1, Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients with Peripheral T-Cell Lymphoma (PTCL)
Study Status
Open
Treatment Agent
Cyclophosphamide,Doxorubicin,Pralatrexate,Prednisone,Vincristine
Principal Investigator
Swaminathan P. Iyer
Description
The goal of this clinical research study is to find the highest tolerable dose of pralatrexate (Folotyn) that can be given in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with PTCL.
General Information
Disease Group: Lymphoma
Treatment Agent: Cyclophosphamide,Doxorubicin,Pralatrexate,Prednisone,Vincristine
Treatment Location: Both at MDACC & and Other Sites
Sponsor: Spectrum Pharmaceuticals, Inc., Allos Therapeutics, Inc.,
Study Status
IRB Review and Approval Date: 02/09/2016
Recruitment Status: Open
Projected Accrual: 30
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Lymphoma
Study phase:
Phase I
Physician name:
Swaminathan P. Iyer
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789